Table 3.
Results of univariate analysis for individual biomarkers and Mammostrat® risk score
| Recurrence-free survival | Distant recurrence-free survival | Overall survival | |
|---|---|---|---|
| ER-positive, tamoxifen treated, node-negative | |||
| SLC7A5 | NS | NS | NS |
| HTF9C | NS | NS | NS |
| NRDG1 | NS | 1.79 (1.11 to 2.88), P = 0.015 | NS |
| CEACAM5 | NS | NS | NS |
| P53 | NS | 1.60 (1.01 to 2.54), P = 0.045 | NS |
| LMH | P = 0.016 | P = 0.003 | NS |
| LvH | 1.78 (1.08 to 2.95), P = 0.025 | 2.30 (1.31 to 4.05), P = 0.004 | |
| LvM | 1.73 (1.12 to 2.68), P = 0.014 | 2.01 (1.21 to 3.35), P = 0.007 | |
| ER-positive, tamoxifen treated | |||
| SLC7A5 | NS | NS | NS |
| HTF9C | 1.61 (1.04 to 2.50), P = 0.032 | 1.87 (1.17 to 2.98), P = 0.008 | NS |
| NRDG1 | 1.45 (1.02 to 2.05), P = 0.037 | 1.83 (1.26 to 2.67), P = 0.001 | 1.64 (1.21 to 2.21), P < 0.0005 |
| CEACAM5 | NS | NS | NS |
| P53 | 1.43 (1.02 to 2.01), P = 0.036 | 1.64 (1.13 to 2.39), P = 0.008 | NS |
| LMH | P = 0.003 | P = 0.0001 | P = 0.006 |
| LvH | 1.80 (1.20 to 2.70), P = 0.005 | 2.23 (1.43 to 3.49), P = 0.0005 | 1.99 (1.17 to 3.41), P = 0.012 |
| LvM | 1.65 (1.15 to 2.35), P = 0.006 | 1.99 (1.33 to 2.97), P = 0.0008 | 1.88 (1.20 to 2.96), P = 0.006 |
| All ER-positive cases | |||
| SLC7A5 | NS | NS | NS |
| HTF9C | NS | 1.51 (1.01 to 2.27), P = 0.048 | NS |
| NRDG1 | 1.51 (1.13 to 2.02), P = 0.005 | 1.84 (1.34 to 2.52), P = 0.0001 | 1.82 (1.42 to 2.34), P < 0.0005 |
| CEACAM5 | NS | NS | NS |
| P53 | 1.39 (1.05 to 1.85), P = 0.02 | 1.56 (1.14 to 2.13), P = 0.005 | NS |
| LMH | P < 0.0001 | P < 0.00001 | P < 0.00001 |
| LvH | 1.80 (1.26 to 2.57) | 2.19 (1.49 to 3.24), P = 0.00008 | 2.16 (1.39 to 3.56), P = 0.0006 |
| LvM | 1.78 (1.31 to 2.40), P = 0.0002 | 2.10 (1.49 to 2.95), P = 0.00002 | 2.26 (1.55 to 3.30), P = 0.00002 |
| All cases | |||
| SLC7A5 | 1.45 (1.08 to 1.95), P = 0.012 | 1.63 (1.19 to 2.22), P = 0.002 | 1.39 (1.06 to 1.80), P = 0.015 |
| HTF9C | 1.45 (1.07 to 1.95), P = 0.015 | 1.57 (1.14 to 2.16), P = 0.005 | 1.37 (1.05 to 1.79), P = 0.021 |
| NRDG1 | 1.58 (1.25 to 2.01), P < 0.0005 | 1.86 (1.43 to 2.40), P < 0.0005 | 1.76 (1.43 to 2.17), P < 0.0005 |
| CEACAM5 | NS | 1.44 (1.03 to 2.02), P = 0.034 | NS |
| P53 | 1.57 (1.25 to 1.98), P < 0.0005 | 1.80 (1.40 to 2.31), P = 0.010 | 1.32 (1.07 to 1.63), P = 0.010 |
| LMH | P < 0.00001 | P < 0.00001 | P < 0.00001 |
| LvH | 2.02 (1.54 to 2.64) | 2.53 (1.89 to 3.40) | 2.62 (1.89 to 3.63) |
| LvM | 1.74 (1.33 to 2.28) | 2.02 (1.49 to 2.73) | 2.24 (1.61 to 3.11) |
All individual markers analyzed as dichotomous variables. ER, estrogen receptor; LMH, P value for significance of Mammostrat® score; LvM, hazard ratio (95% confidence interval) for low-risk versus medium-risk cases classified by Mammostrat®; LvH, hazard ratio (95% confidence interval) for low-risk versus high-risk cases classified by Mammostrat®; NS, nonsignificant.